ONQVIEW

Non-Radioactive Molecular Imaging-Driven Drug Development in Oncology

 Coordinatore ACADEMISCH ZIEKENHUIS GRONINGEN 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 2˙499˙989 €
 EC contributo 2˙499˙989 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2011-ADG_20110310
 Funding Scheme ERC-AG
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-04-01   -   2017-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITEIT TWENTE

 Organization address address: DRIENERLOLAAN 5
city: ENSCHEDE
postcode: 7522 NB

contact info
Titolo: Mr.
Nome: Ferdinand
Cognome: Damhuis
Email: send email
Telefono: +31 53 4894019
Fax: +31 53 4894841

NL (ENSCHEDE) beneficiary 702˙240.00
2    ACADEMISCH ZIEKENHUIS GRONINGEN

 Organization address address: Hanzeplein 1
city: GRONINGEN
postcode: 9713 GZ

contact info
Titolo: Dr.
Nome: Gerda
Cognome: G. Klooster
Email: send email
Telefono: 31503614245
Fax: 31503614862

NL (GRONINGEN) hostInstitution 1˙797˙749.40
3    ACADEMISCH ZIEKENHUIS GRONINGEN

 Organization address address: Hanzeplein 1
city: GRONINGEN
postcode: 9713 GZ

contact info
Titolo: Prof.
Nome: Emma Geertruida Elisabeth
Cognome: De Vries
Email: send email
Telefono: +31 50 3612934
Fax: +31 50 3614862

NL (GRONINGEN) hostInstitution 1˙797˙749.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

optical    tumor    tracers    drug    photoacoustic    colon    treatment    drugs    tuning    pre    radioactive    cancer    breast    behavior    molecular    clinical    imaging    dynamic   

 Obiettivo del progetto (Objective)

'Cancer is a leading cause of death worldwide. Fortunately an abundance of cancer drugs are becoming available; the challenge now is to select the most promising. Integrated cancer research and biomarker-driven adaptive and hypothesis-testing clinical trials are imperative. Many tumor characteristics can now be visualized simultaneously, but the necessary tracers have hardly been explored clinically. In the onQview program, we aim to create a drug development strategy based on a novel non-radioactive molecular imaging approach to guide patient-tailored selection of drugs, to measure in vivo drug and tumor behavior, and to allow dynamic treatment tuning. Our extensive (pre)clinical experience with molecular imaging and drug development is hereby merged with our unique infrastructure, including lasers, microscopes, and advanced detection systems for non-ionizing electromagnetic waves, for optical and photoacoustic imaging modalities. We will develop novel non-radioactive tracers based on HER-targeting drugs in breast and colon cancer, and use molecular imaging to track the drugs and corresponding effect sensors that visualize targeting effects. This approach will allow dynamic treatment tuning in pre-clinical (animal) experiments. We will also advance the implementation of optical and photoacoustic imaging with optimized measurement techniques and quantification strategies that will allow testing of the new tracers in breast/colon cancer models. Two tracers will be produced for human use and evaluated in clinical studies that enable visualization of drug behavior, drug targets and drug effects in relation to the HER family in breast and colon cancer.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

FPCMB (2011)

Fundamental Physics from the Cosmic Microwave Background

Read More  

MIGPROSP (2014)

Prospects for International Migration Governance

Read More  

DOJSFL (2013)

"The Dissolution of the Japanese Empire and the Struggle for Legitimacy in Postwar East Asia, 1945-1965"

Read More